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1. Introduction 
The first beta- lactamases were identified in a species of E.coli in 1940 (1). However, the 
ability of bacteria to produce enzymes that destroy the b-lactam ring was noted even before 
penicillin was developed. In fact, many of the gram-negative bacteria possess 
chromosomally mediated b- lactamases, which help the bacteria find a niche when faced 
with competition from other bacteria that naturally produce b-lactams. 
In 1965, the first plasmid mediated beta- lactamases was discovered. This occurred in a 
strain of E.coli isolated from the blood culture of a patient from Greece whose name was 
Temoniera.  The beta -lactamases was named TEM-1 after the patient’s name from whom it 
was isolated. (2) This strain soon spread to other members of the Enterobacteriaceae species, 
Hemophilus influenza, Neisseria gonorrhoeae and Pseudomonas aeruginosa due to the plasmid 
mediated transfer. 
Around the same time a second plasmid mediated beta-lactamases was found in Klebsiella 
pneumonaie and E.coli. This was called SHV-1 (sulfhydryl variable) (3).  The advent of the b- 
lactam class of antibiotics was influenced largely by the discovery of these enzymes. An 
example of this was the development of oxyimino-cephalosporin, which showed good 
stability against the TEM-1 and SHV-1 b-lactamases (4). This class of antibiotics soon became 
the workhorse for these types of serious infections.  
Unfortunately, resistance to this class soon became evident in 1985 with beta-lactamases 
showing the ability to hydrolyze these compounds in K.pneumoniae  (5). Because this enzyme 
was noted to be active against expanded spectrum b-lactams these enzymes were labeled as 
“extended spectrum beta-lactamases” –ESBL. 
Several b-lactamases have continued to be with over 130 TEMS types and over 50 SHV types 
known to date. These are mainly found in E.coli, K.pneumoniae and P.mirabilis, but have also 
been found in other species of the Enterobacteriacae family and even in some nonenteric 
bacteria such as Acinetobacter species. 
Shortly after the introduction of new broad-spectrum cephalosporins such as cefotaxime 
and ceftazidime, non-TEM and non SHV ESBL’s were discovered. This new class of ESBL’s 
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has been called CTX-M in reference to the potent hydrolytic activity of these enzymes 
against cefotaxime(6). There are over 40 of these enzymes reported.  CTX-M producing 
ESBL pathogens usually have cefotaxime in the resistant range (MIC>64).   
More recently, and of greater concern is the occurrence of carbapenemases which show 
activity against oxyimino-cephalosporins and cephamycins but also against carbapenems 
(7). There are two major groups in this class called metallo-b-lactamases (Verona integron 
encoded metallo b lactamases) (VIM) and carbapenemases. Structural studies of ESBL 
indicate that active site expansion and remodeling are responsible for the extended 
hydrolytic activity (8).These enzymes are globally present and appear to cause clinically 
significant disease such as urinary tract infections, abscesses and bacteremia.  
With the advent of the ESBL pathogens, there has been a significant increase in the 
morbidity and mortality related to these infections. If the number of carbapenemase- 
producing organisms continues to increase, the treatment options will be seriously 
compromised. 
In addition, ESBL producing pathogens are not only resistant to penicillin and 
cephalosporins but also to trimethoprim-sulphamethoxazole and fluroquinolones which can 
compromise the treatment of both nosocomial and community acquired infections caused 
by Enterobacteriaceae and other species (9). 
One of the major clinical problems has been the recognition of both nosocomial and 
community acquired urinary tract infections resulting from ESBL pathogens. The treatment 
options for these infections are limited, especially in the out patient setting.  
This chapter will review the epidemiology, risk factors, clinical features and therapeutics 
options for ESBL-induced infections of the urinary tract. 
2. Recent epidemiological data 
ESBL producing organisms have been implicated in nosocomial infections. Over the last 
decade, there has been a steady increase of these infections in the community.  
In fact, a recent study from Spain suggest there was been an increase in ESBL E.coli 
producers from 0.3% to 4.8% between 1995 and 2002. (10) Interestingly, during this same 
period there was a drop in the rate of ESBL producing K.pneumoniae following the control of 
nosocomial transmission of this pathogen. These K. pneumoniaie were mostly clonally related 
and produced SHV and TEM.  
In contrast, the ESBL E.coli strains were not clonally related and the predominant strain was 
a CTX-M. In addition, half of these strains were isolated from outpatients (10,11). 
France was one of the first countries to report an outbreak of ESBL infections in 1986. In this 
study, 30% of Enterobacter aerogenes isolates in 2000 were ESBL producers (12). Since that 
time, virtually every country in Europe has reported ESBL producers with considerable 
geographical variability in the occurrence of ESBL’s. Examples of this include a prevalence 
rate of ESBLs  
K. pneumoniaie in Sweden of 3% to 34% in Portugal (13). In one study done in France, it was 
noted that intestinal carriage prevalence of ESBL-E.coli was 8.0%, mainly the CTX-M type. 
At the same time, it was noted that there was an increase in antibiotic usage, especially the 
beta-lactams. This variability probably occurred because of the repeated introduction of new 
strains and plasmids and from inter-individual dissemination (14) 
In Central and South America ESBL, rates in Klebsiella varied from 30 to 60% in countries 
such as Brazil, Columbia and Venezuela (15). The ESBL strains included SHV-2, 5, CTX-M 
and even non-TEM and non-SHV with no geographical predilection. (16, 17) 
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In Africa and the Middle East there has been a number of outbreaks of ESBL producing 
infections from South Africa to northern Africa. The rates of ESBL were variable depending 
on the country (18 19) . 
In North America the first case of an ESBL producer was in 1988and since then a variety of 
infections produced by TEM strains, SHV type and CTM-X have been reported.  In fact, in a 
recent survey it was noted that non-susceptibility to third generation cephalosporin’s may 
be as high as 13 %.( 20,21). In the outpatient, setting 1.8% of k.pneumoniae and 0.4% were 
ceftazidime resistant (22) 
In Asia, there seems to be a larger proportion of ESBL pathogens. Studies from several 
countries, including China, India, Japan, Korea, and Malaysia showed ranges from 30% to 
40 % (23,24). Reports of a possible predominant CTM-X ESBL in countries like India, China 
Korea, Japan and Taiwan indicate that there may be a dominant ESBL type in Asia (25,26). 
More recently, there have been studies showing increasing numbers of carbapenemase 
producing pathogens, which is of increasing clinical importance due to the lack of effective 
antimicrobial therapy. (27-31). 
Current data suggest that the incidence of ESBL producing infections is on the rise globally 
resulting in increasing difficulty in the diagnosis and treatment of these infections. 
3. In vitro resistance studies for ESBL 
In- vitro susceptibility testing of cephalosporins for ESBL producing enterobacteriacae can be 
misleading. Testing may suggest that an isolated strain is susceptible to a given 
cephalosporin, but the drug may not be effective when used to treat a serious infection 
caused by the organism. Thus, CLSI guidelines recommend that laboratories report ESBL 
producing isolates as resistant to all penicillin’s, cephalosporins and aztreonam irrespective 
of in vitro results. (32). 
In vitro studies performed in Turkey found that E.coli isolated from CA-UTI infections had 
simultaneous resistance to trimethoprim-sulphamethaxazole, ciprofloxacin, and gentamicin 
in 4.6% of an ESBL negative group and 39.2% in the ESBL positive group. 90% of these ESBL 
isolates were found to have CTX-M 15. (33). This data is worrisome as therapeutic options 
are limited when oral antibiotics are used. 
 In Taiwan, Lau and colleagues looked at 201 patients with and without bacteremia in CA-
ESBL UTI. They found that e.coli was the most common pathogen and was more frequent in 
the bacteremic than non-bacteremic group. Non-E.coli isolates such as K.pneumoniae, 
Morganella morganii etc were more common in the non-bacteremic group. E.coli isolates had 
a high rate of resistance to ampicillin (80%), gentamicin (29%) trimethoprim-
sulphamethaxazole (56%). (34). Similar findings have been documented from other parts of 
the world such as Saudi Arabia  (35). 
Detection of ESBL’s is based on the fact that ESBL producers should be reported as resistant 
to all penicillin’s, cephalosporins (except cephamycins) and aztreonam irrespective of 
routine antimicrobial susceptibility testing. (32) 
Both broth dilution and disk diffusion can be used for the screening of ESBL producers. 
Specific phenotypic confirmatory tests should be done if the E.coli, K.pneumoniae, show 
MIC’s>8ug/ml for cefpodoxime or MIC’s >2 ug/ml against ceftazidime, cefotaxime or 
aztreonam. (36,37) 
The E-test can also be used in the detection of ESBL. Automated methods for bacterial 
identification and susceptibility testing are also used in the detection of ESBL producing 
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organisms. These include the BD Phoenix system, Vitek 2 system and the Micoscan 
Walkway -96 system.   
4. Risk factors for colonization /infection with ESBL 
There have been several case controlled studies looking at the risk factors for colonization 
with or without infection due to ESBL producers. However, the results are conflicting due to 
study populations, geographical areas, selection of cases and controls and sample size. (38-
48). 
Despite these statistical differences, some generalizations can be made. (Table 1) 
 
Diabetes mellitus 
Previous antimicrobial exposure (quinolones, third generation cephalosporins, penicillin) 
Previous hospital admissions 
Older age 
Male patients 
Table 1. Risk factors for the Development of Community ESBL Infections. 
Some of these risk factors include seriously ill patients with prolonged hospital stays (11-67 
days) who have usually had multiple invasive devices and co-morbidities such as urinary 
catheters, central lines, nasogastric tubes, jejunostomy tubes, arterial lines, total parental 
administration, recent surgery, decubitus ulcers, hemodialysis catheters and poor 
nutritional status.   
The use of previous antibiotics such as third generation cephalosporins, quinolones, 
trimethoprim-sulphamethoxazole, aminoglycosides and metronidazole have also been 
implicated in several studies. (38,42,45,49,44,50,47, 48,51).  
5. Community –acquired infections involving ESBL pathogens 
In a large French study in 1993, looking at E.coli, K.pneumoniae and P .mirabilis (2500 isolates) 
from non-hospitalized patients, there was no evidence of community acquired ESBL 
infections (52). Since then, there have been several studies of true community acquired ESBL 
infections. These involved patients with diarrheal diseases such as Shigella, Salmonella, Vibrio 
cholerae and E. coli. (53-56) 
The prevalence of colonization with enterobacteria is unknown.  The percentage of ESBL 
producing Enterobacteria faecal carriers in Spain increased from 2.1% to 7.5% IN 2002. (57) . 
The most frequent types of ESBL were CTX-M, followed by SHV. In India, the rate of fecal 
carriage was 7% in a sample of healthy adults (60). In Canada, Pitout found 5.5 cases per 
100,000 populations with 69% being community acquired. (59) 
Three case controlled studies looking at risk factors for ESBL E.coli outpatient infections 
found that diabetes mellitus, previous use of antibiotics such as quinolones and 
cephalosporins, recurrent urinary tract infections, prior hospital admissions and older age 
were independent risk factors (59,60). However, infections due to ESBL producing E.coli in 
patients can occur without obvious risk factors. This may be related to the increase in 
healthy carriers colonized with this pathogen.  
Colodoner et al evaluated 128  cases of UTI caused by ESBL E.coli and K. pneumoniae and 
found that age >60 years, male sex, previous use of quinolones or cephalosporins, previous 
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hospitalization, and previous infections caused by K. pneumoniae were independent risk 
factors.(61) 
In community- acquired urinary tract infection (CA-UTI), the rate of ESBL associated UTI’s 
varied from 1.4% in Spain up to 3.3% in the Gaza strip (60,62,63). 
In the last 7 years, there have been an increasing number of publications from several 
countries showing and increase of community acquired ESBL infections, mainly in urinary 
tract. (64,65,61,57,30,59,60,31) Most of these patients had urinary tract infections (UTI’s) with 
genes encoding for CTM-X type of ESBL’s (60). Recently, there has been an increase in the 
diagnosis of infections caused by ESBL E.coli producers diagnosed in the outpatient’s 
setting.(59,60,30)  
Romero et al showed an increase from 0.3% in 1995 to 4.8% in 2002 in community acquired 
ESBL E.coli producers. (10). These ESBL E.coli producing strains were not clonally related 
with the majority belonging to the CTX-M family and more than 50% were isolated in the 
outpatient setting. (10, 11) 
In one study in Spain up to 6.5% of community, acquired bacteremia was associated with 
ESBL E.coli UTI (60).  
In summary, ESBL infections can range from colonization to carriage to true infections 
involving sepsis syndromes and bacteremia.  
6. Clinical features of CA-UTI infections caused by ESBL pathogens 
Several studies have described the microbiological features of ESBL producing organisms in 
the outpatient setting. However, very few studies have correlated the microbiological 
findings with that of the clinical features and prognosis of these CA-UTI ESBL infections. 
Therefore, one may only draw some tentative conclusions from these studies.   
In urinary tract infections, the majority of ESBL’s isolated, not surprisingly, have been ESBL 
E.coli. This organism has also been isolated from other sources such as wounds, sputum, and 
occasionally blood. (59,60,11,) 
In the United States, Chao Qi et al evaluated 193 single patient ESBL isolates in outpatient 
urine cultures during a 5-year period. 3% of E.coli had ESBL and this was noted to have 
increased 14 times from 2003 to 2008. This increase may have been in part due to the 
dissemination of CTX-M type of ESBL. (66) This was also noted in another study from 
nursing homes and out patient clinics. (67) . Resistance to ciprofloxacin and trimethoprim-
sulphamethaxazole was much higher as well. 
In another study of 49 patients with ESBL E.coli infections, ESBL E.coli was isolated from 
urine in 47 of the cases and from blood in 6 of the patients. Thirty-seven (76%) of these 
patients were considered to have symptomatic infections and 11 (22%) asymptomatic 
bactiuria. 1 patient also had cholangitis and 6 (13.5%) of these patients were bacteremic. In 
this same study, 10 of the 28 patients who received antibiotics actually received an 
appropriate agent to which the organism was susceptible in vitro. 13% of these patients had 
a UTI relapse. There were no deaths in this study (60). It appears that the complication rate 
with CA-ESBL UTI’s may not be higher than that associated with routine non-ESBL 
pathogens, although further studies are still needed. The main predictor of mortality caused 
by ESBL E.coli is probably inadequate initial antimicrobial therapy. In comparison, ESBL-EC 
associated mortality for hospitalized patients with serous infections such as bacteremia and 
sepsis was about 25%-31%. This was also associated with inadequate empiric antibiotic 
therapy. (68,69). 
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The most frequent cause of community-acquired bacteremia is E.coli (70,71) and currently 
available antibiotics such as quinolones, beta-lactams and third generation cephalosporins 
are commonly used to treat them. This may need to change with the advent of increasing 
antimicrobial resistance and increasing mortality associated with these CA-ESBL infections 
(44,59). Rodriguez-Bano examined CA-ESBL associated bacteremia and its features and 
found that in 95 patients with blood stream infections 7.3% were due to E.coli. The majority 
belonged to the CTX-M family of ESBL and was clonally unrelated. The risk factors 
associated with these patients included urinary foley catheter use and previous 
antimicrobial exposure (60). The sources of bacteremia were the urinary tract, intra-
abdominal sites and respiratory tract. Interestingly, mortality associated with blood stream 
infections due to ESBL-E.coli was lower among patients who received empirical therapy 
with beta-lactam or it combinations or carbapenems than among those that received 
quinolones. In addition, higher mortality was associated with inappropriate empirical 
therapy in patients with bacteremia due to E.coli. (72) 
In patients with solid organ transplants and renal transplants, the major site of infection was 
the urinary tract in 72% of the cases, with ESBL .K. pneumoniae being more common in renal 
transplant patients ( 73). 
Geriatric patients with ESBL UTI’s pose an unusual clinical problem. These patients may be 
chronically colonized in either the gastrointestinal tract or the skin and reinfection is a 
possibility. In addition, many of these patients are asymptomatic and do not present with 
the classic symptoms of dysuria, frequency of urination, fever or leukocytosis. In general, 
one may not need to treat asymptomatic ESBL infections. If there is a change in the clinical 
status such as fever, leukocytosis or altered mental status then treatment options should be 
considered. Numerous outbreaks have been reported of patients with ESBL infections. 
Much of the spread is plasmid mediated and is therefore through direct and indirect 
transmission. Contact isolation should be instituted in patients with ESBL infections. 
In summary, ESBL infections can present from simple colonization to active UTI’s and to 
serious bacteremia associated with sepsis syndrome.  
7. Treatment options for ESBL UTI infections 
Treatment options for ESBL infections are the same for both nosocomial and community 
acquired infections. The major problem at this time is the lack of effective oral antibiotics for 
the treatment of outpatient ESBL infections.  
7.1 Overview of available antibiotics 
ESBL’s hydrolyze aztreonam, penicillin and cephalosporins (with the exception of 
cephamycins) with varying degrees of hydrolytic activity. Usually the TEM and SHV type 
ESBL’s have greater hydrolytic activity for ceftazidime than for cefotaxime (74). Therefore, 
ESBL producing organisms may appear susceptible to some of the above-mentioned 
antibiotics in vitro. In addition, there is frequent co –expression of resistance by these 
organisms to classes of antimicrobial agents other than those hydrolyzed by the ESBL’s. This 
has been documented for quinolones, aminoglycosides, tetracycline’s (excluding 
glycylcycline) and trimethoprim-sulphamethoxazole (59) 
Some of the other antibiotic classes used to treat  ESBL infections include beta lactam/beta-
lactamases inhibitors. The level of activity for these agents varies by the type of inhibitor 
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and by the class of ESBL. For example, tazobactam appears to be more effective than 
clavulanic acid against certain types of CTX-M type ESBL’s and both of these agents are 
more effective than sulbactam in inhibiting TEM and SHV type ESBL. (75,76). This data is 
mainly from in-vitro studies. Clinical information is sparse in regards to beta-lactam and 
inhibitor combinations, but some favorable outcomes have been reported with 
pipercillin/tazobactam. However, it is important to note that favorable results have not 
been consistently reported (74,77). One possible oral option may be amoxicillin/clavulanate, 
which has shown some activity in CA-ESBL Enterobacteriaceae UTI infections (60,78) 
Few studies have evaluated cephalosporins in the treatment of both bacteremic and non-
bacteremic ESBL infections. The results have been equivocal when ceftazidime or cefepeme 
were compared to Imipenem in e. coli bacteremia and in ICU patients with 
Enterobacteriaceae infections. (79,80). In vitro data also suggests suboptimal outcomes when 
the cephalosporins were used to treat ESBL infections. Thus, most experts’ advise against 
using cephalosporins in the treatment of ESBL associated infections.(79,80) 
Cephamycins have not been well studied in the treatment of ESBL associated infections. In 
one small retrospective study,  there was no obvious difference in the mortality rates 
between the cephamycins and carbapenems. Recent studies have documented resistance to 
the cephamycins (49,74). 
The glycylcycline class of antibiotics, specifically tigecycline, thus far evaded the common 
mechanisms of resistance in both gram positive and gram-negative pathogens. It has 
excellent in vitro activity against ESBL-E.coli and K. pneumoniae. However, clinical data is 
sparse in the treatment of ESBL UTI’s and bacteremia. In addition, only a fraction of the 
drug is excreted in the urine as unchanged drug. In addition, tigecycline does not achieve 
high concentrations in the blood,  casting doubts on its potential effectiveness in the 
treatment of bacteremia.(81)  
Fosfomycin has been used in Europe but is not available in most parts of the world. It is a 
phosphor derivative of streptomycin and inhibits cell wall synthesis and impairs adherence 
to urogenital mucosa. A study in Spain found that the resistance rate to fosfomycin of  
ESBL-EC was 0.3%. (82). It has been used in cystitis and asymptomatic UTI in pregnancy. 
(82,83). In the United States 90% of the isolates in one study were susceptible to fosfomycin 
and to a combination of cefdinir plus amoxicillin-clavulanate. (84,85) 
Pivmecillinam is a beta lactam antibiotic, which binds penicillin-binding protein 2 (PBP-2) 
and inhibits cell wall synthesis. This drug has been used in the treatment of cystitis due to 
Enterobacteriaceae. (86). 
Nitrofurantoin is a bactericidal drug, which acts by altering bacterial ribosome’s proteins 
and can be used for UTI as well. 
Finally, carbapenems are considered the drug of choice for ESBL infections. All the drugs in 
the class appear to have the same efficiency in the treatment of ESBL. Ertapenem, is the only 
drug in this class that can be administered once a day. It can be used in the outpatient 
setting as long as the in vitro activity is similar to imipenem, doripenem or 
meropenem.(87,88). However, recent reports of carbapenem resistance have emerged and 
the spread of resistance is of concern. One possible option might  be to add amikacin to the 
empiric regimen in community-acquired sepsis originating in the urinary tract since 
amikacin resistance among CTX-M isolates is relatively low. 
The treatment for upper UTI’s may have to be limited to the intravenous antibiotics 
mentioned above especially as the patients tend to be sicker and may present with systemic 
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inflammatory response syndrome and occasionally bacteremia. These should include 
carbapenems. Occasionally, ampicillan-sulbactam and tigecycline may be alternate therapies 
although data on these drugs in the treatment of ESBL  UTI infections is sparse. 
In lower UTI‘s, some of the oral antibiotics such as nitrofurantoin, fosphomycin, amoxicillin-
clavulanate and trimethoprim-sulphamethaxazole may be used if the pathogen is 
susceptible to them. 
8. Conclusion 
Antimicrobial resistance has become a global problem of increasing importance. It is now 
essential that laboratories be able to rapidly identify and characterize resistant organisms.  
This is, of even more importance, in ESBL producing organisms that clearly have a higher 
morbidity and mortality associated with their infections. There is also increasing evidence, 
that ESBL organisms frequently possess resistance factors to other classes of other 
antimicrobials, like the aminoglycosides and quinolones. ESBL producing bacteria are being 
found both in the hospital and in the community, especially the CTX-M beta –lactamases. 
The increasing number of community isolates, especially E. coli producing CTX-M-15 have 
become global and now are being seen in the hospital as well. It is thought that the CTX-M -
15 producing E.coli is mostly due to a single clone named ST131, which appears to have 
originated in the Indian sub-continent. In addition, the increasing number of 
carbapenemases could also seriously compromise our treatment options. Therefore, empiric 
antimicrobial coverage may need to be modified in patients who present with serious sepsis 
syndromes, especially,  after travel to countries that are high risk for this clone. 
Treatment of ESBL infections requires the use of carbapenems in seriously ill patients. 
Imipenem, meropenem, doripenem are all viable alternatives. Ertapenem can be used in the 
out patient setting, in the absence of Pseudomonas aeruginosa. Agents such as fosfomycin, 
nitrofurantoin, amoxicillin/clavulanic acid, pivemecillinam, temocillin can be alternate 
drugs in uncomplicated UTI’s and in patients with drug allergies to the carbapenems. 
Salvage therapy using tigecycline and colistin can be used in seriously ill patients who are 
CTX-M producers and Amp-C producing isolates.  
In addition to understanding the complex mechanisms involved in ESBL infections, strict 
antimicrobial stewardship, appropriate infection control measures and aggressive treatment 
of seriously ill patients is necessary in reducing the mortality and morbidity associated with 
these infections. 
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